Qiming Medical-B (02500) announced interim results, with a loss of 191 million yuan to the mother, an increase of 41.9% year-on-year

According to the Zhitong Finance App, Qiming Medical-B (02500) announced interim results for the six months ended June 30, 2026. The group obtained revenue of RMB 135 million (same unit), a year-on-year decrease of 27.6%; losses attributable to owners of the parent company amounted to RMB 191 million, an increase of 41.9% over the previous year; and a loss of 0.44 yuan per share.

The announcement stated that the decline in revenue was mainly due to the domestic market. Under the dual influence of the National Health Insurance Administration's negotiations on the reduction in the terminal price of TAVR products and the intensification of market competition due to the approval and listing of more manufacturer products, the factory price and sales volume of domestic TAVR products all declined somewhat compared to the same period last year. Overseas business maintained a steady growth trend during the reporting period, but the increase in revenue did not fully offset the impact of the decline in domestic business.